All In Biotech

Drug Trial Radar · NCT03142139

Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?

Timing of Vaccination With the Non-live DTaP-IPV-Hib Vaccine and Development of Atopic Dermatitis Before 1 Year of Age - a Danish Register Based Cohort Study

Last checked: Nov 19, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,027,559

Actual

Start

Jan 1, 1997

Primary completion

Dec 31, 2014

Study completion Dec 31, 2014

Sponsor

Lead sponsor
Bandim Health ProjectAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Murdoch Childrens Research Institute
First posted
May 5, 2017

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 24 months, up to 24 months

Summary

As written by the sponsor on the registry.

It has been found that the non-live vaccine against Diphtheria, Tetanus, and Pertussis (DTP) in addition to its disease specific effects may have so called "non-specific effects" with the potential to affect sensitivity towards vaccine unrelated pathogens, resulting in excess mortality(Aaby, Kollmann, \& Benn, 2014). A recent study from Australia found that delayed vaccination with the first dose of Diphtheria, Tetanus, and acellular Pertussis(DTaP)-containing vaccine is associated with reduced risk of atopic dermatitis (aOR: 0.57; 95% CI: 0.34-0.97, P = 0.04) and reduced use of medication against atopic dermatitis (aOR: 0.45; 95% CI: 0.24-0.83, P = 0.01)(Kiraly et al., 2016). This register based observational study aims to extend the existing knowledge on non-specific effects of non-live vaccines by testing the above finding, that delayed vaccination with Diphtheria, Tetanus, acellular Pertussis - Inactivated Polio vaccine - Haemophilus influenzae type b (DTaP-IPV-Hib) is associated with lower risk of developing atopic dermatitis before 1 year of age in the Danish birth cohorts from 1997-2012.

Conditions

  • Atopic Dermatitis

Interventions

  • RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-HibBiological

    Children will be categorized as "timely vaccinated" if they receive the 1st dose within the month of scheduled vaccination: * "timely vaccinated": received 1st dose of DTaP-IPV-Hib before 4 months of age * "delayed vaccinated": did not receive the first dose of DTaP-IPV-Hib before 4 months of age.

  • RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-HibBiological

    Children will be categorized as "timely vaccinated" if they receive the 2nd dose within the month of scheduled vaccination: * "timely vaccinated": received 2nd dose of DTaP-IPV-Hib before 6 months of age * "delayed vaccinated": did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age.

  • RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinatedBiological

    • Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as "unvaccinated" until date of vaccination where they will shift exposure group to "vaccinated".

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Atopic dermatitis (AD)Time frame: RQ1.a+ 1.b: Registered AD from baseline until 12 months of age. RQ2: AD is assessed from baseline (3 months of age) through follow-up (until 8 months of age)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.